Showing results (541-550 of 782) with videos related to

Sort By:
Pageof 79
The Lancet. HIV|February 28, 2024
Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trialGraeme Moyle, Lambert Assoumou, Nathalie de Castro, et al.
The Lancet. HIV|February 28, 2024
Centring the health of women across the HIV research continuumElizabeth Barr, Leslie J Marshall, Lauren F Collins, et al.
The Lancet. HIV|June 2, 2024
Transition times across the HIV care continuum in Spain from 2005 to 2022: a longitudinal cohort studyAlejandro G García-Ruiz de Morales, María Jesús Vivancos, María de Lagarde, et al.
The Lancet. HIV|May 2, 2024
Two-drug regimens for the treatment of HIV in AfricaIvan Mambule, Claire Norcross, Loice Achieng Ombajo, et al.
The Lancet. HIV|November 12, 2023
Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trialRaphael J Landovitz, Brett S Hanscom, Meredith E Clement, et al.
The Lancet. HIV|November 12, 2023
Post-exposure prophylaxis to prevent HIV: new drugs, new approaches, and more questionsKenneth H Mayer, Lao-Tzu Allan-Blitz
The Lancet. HIV|October 14, 2023
Haematopoietic stem-cell transplantation in an HIV endemic area: time to consider donors exposed to or living with HIVCandice Laverne Hendricks, Juanita Mellet, Chrisna Durandt, et al.
The Lancet. HIV|October 12, 2023
HIV and fungal priority pathogensHatim Sati, Ana Alastruey-Izquierdo, John Perfect, et al.
The Lancet. HIV|October 6, 2023
Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trialMagdalena E Sobieszczyk, Sharon Mannheimer, Carmen A Paez, et al.
The Lancet. HIV|October 11, 2024
Extreme weather events and disruptions to HIV services: a systematic reviewCollins C Iwuji, Celia McMichael, Euphemia Sibanda, et al.
Pageof 79